---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-037887"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:31:51.929476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy

## Summary
- Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.
- Builds on existing pelacarsen collaboration; Novartis to handle development and commercialization.
- Agreement subject to HSR antitrust clearance.
- Ionis eligible for additional milestone payments and tiered royalties.

## SEC filing metadata
- accession: 0001140361-23-037887
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/0001140361-23-037887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/brhc20056974_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-037887
- JSON: https://secwatch.observer/filing/0001140361-23-037887.json
- Plain text: https://secwatch.observer/filing/0001140361-23-037887.txt

## Key facts
- Material Agreements
  IONIS PHARMACEUTICALS INC entered into Agreement with Novartis Pharma AG (effective 2023-08-03).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Novartis Pharma AG
  - Effective: 2023-08-03
  source text: On August 3, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that the Company entered into a collaboration and license agreement (the “ Agreement ”) with Novartis Pharma AG (“ Novartis ”) to discover, develop and commercialize a novel medicine for patients with lipoprotein(a)-driven cardiovascular disease.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/0001140361-23-037887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.